The role of integrins in melanoma: a review

被引:20
作者
Arias-Mejias, Suzette M. [1 ,2 ]
Warda, Katerina Y. [1 ]
Quattrocchi, Enrica [1 ]
Alonso-Quinones, Hector [2 ]
Sominidi-Damodaran, Sindhuja [1 ]
Meves, Alexander [1 ]
机构
[1] Mayo Clin, Dept Dermatol, Rochester, MN USA
[2] Mayo Clin, Ctr Clin & Translat Sci, Rochester, MN USA
关键词
PHASE-II TRIAL; ALPHA-2-BETA-1; INTEGRIN; MONOCLONAL-ANTIBODY; MALIGNANT-MELANOMA; GENE-EXPRESSION; BETA-3; CELL-ADHESION; ALPHA-V; CANCER; ALPHA(V)BETA(3);
D O I
10.1111/ijd.14850
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Integrins are the major family of cell adhesion receptors in humans and essential for a wide range of normal physiology, including formation and maintenance of tissue structure integrity, cell migration, proliferation, and differentiation. Integrins also play a prominent role in tumor growth and metastasis. Translational research has tried to define the contribution of integrins to the phenotypic aggressiveness of melanoma because such knowledge is clinically useful. For example, differential expression of integrins in primary cutaneous melanoma can be used to distinguish indolent from aggressive, prometastatic melanoma. Recent studies have shown that gene expression-based testing of patient-derived melanoma tissue is feasible, and molecular tests may fully replace interventional surgical methods such as sentinel lymph node biopsies in the future. Because of their central role in mediating invasion and metastasis, integrins are likely to be useful biomarkers. Integrins are also attractive candidate targets for interventional therapy. This article focuses on the role of integrins in melanoma and highlights recent advances in the field of translational research.
引用
收藏
页码:525 / 534
页数:10
相关论文
共 86 条
  • [1] ALBELDA SM, 1990, CANCER RES, V50, P6757
  • [2] Alday P, 2019, CANCERS, V11
  • [3] Circulating Tumor Cells and Circulating Tumor DNA
    Alix-Panabieres, Catherine
    Schwarzenbach, Heidi
    Pantel, Klaus
    [J]. ANNUAL REVIEW OF MEDICINE, VOL 63, 2012, 63 : 199 - 215
  • [4] Integrins in angiogenesis and lymphangiogenesis
    Avraamides, Christie J.
    Garmy-Susini, Barbara
    Varner, Judith A.
    [J]. NATURE REVIEWS CANCER, 2008, 8 (08) : 604 - 617
  • [5] A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer
    Bell-McGuinn, Katherine M.
    Matthews, Carolyn M.
    Ho, Steffan N.
    Barve, Minal
    Gilbert, Lucy
    Penson, Richard T.
    Lengyel, Ernst
    Palaparthy, Rameshraja
    Gilder, Kye
    Vassos, Artemios
    McAuliffe, William
    Weymer, Sara
    Barton, Jeremy
    Schilder, Russell J.
    [J]. GYNECOLOGIC ONCOLOGY, 2011, 121 (02) : 273 - 279
  • [6] Developments in the treatment of early NSCLC: when to use chemotherapy
    Besse, B.
    Le Chevalier, T.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 52 - 59
  • [7] The Therapeutic Antibody LM609 Selectively Inhibits Ligand Binding to Human αVβ3 Integrin via Steric Hindrance
    Borst, Andrew J.
    James, Zachary M.
    Zagotta, William N.
    Ginsberg, Mark
    Rey, Felix A.
    DiMaio, Frank
    Backovic, Marija
    Veesler, David
    [J]. STRUCTURE, 2017, 25 (11) : 1732 - +
  • [8] A nine-gene signature predicting clinical outcome in cutaneous melanoma
    Brunner, G.
    Reitz, M.
    Heinecke, A.
    Lippold, A.
    Berking, C.
    Suter, L.
    Atzpodien, J.
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (02) : 249 - 258
  • [9] Integrin Structure, Activation, and Interactions
    Campbell, Iain D.
    Humphries, Martin J.
    [J]. COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY, 2011, 3 (03): : 1 - 14
  • [10] Clinical Application of Radiolabeled RGD Peptides for PET Imaging of Integrin αvβ3
    Chen, Haojun
    Niu, Gang
    Wu, Hua
    Chen, Xiaoyuan
    [J]. THERANOSTICS, 2016, 6 (01): : 78 - 92